Stockreport

High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin [Yahoo! Finance]

Palvella Therapeutics, Inc.  (PVLA) 
PDF On December 16, 2025, analyst confidence in Palvella Therapeutics, Inc. (NASDAQ:PVLA) was seen rising, as the company announced encouraging Phase 2 data for QTORIN rapa [Read more]